adconl pharmaceutical gel designed reduce incidence severity scarring back operations consists combination marginally watersoluble artificial sugars reabsorbed body within several months application gel marketed united states gliatech approved fda eventually sold wright medical technologies result gliatech going four randomized controlled trials particular interest done regarding adconls effect scarring clinical outcomes three tests done europe one united states together trials consisted patients treated gel patients acting control group first trial done determined adhesion reduced severity scarring postoperation well minor improvements clinical outcomes second trial occurring united states first agreed first trial results given independent investigators investigators declared effect scarring using adconl effect clinical outcome two trials led different conclusions based first trial original study second gel reduces scars certain benefit clinical outcome conclusion based first trial reworked second trial claiming results suggest practical use adconl recommended due conflicting results two randomized controlled trials done concluding effects scaring clinical outcome regarding adconl based four trial strong conclusions dermatologic drug article stub help wikipedia expanding httpsenwikipediaorgwikiadconl